Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10019173HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10019323HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10031044HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10025139HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10020261HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10040464HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS20001928HPVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TCGA Plot Options
Drug Information
GeneADRA1A
DrugBank IDDB00243
Drug NameRanolazine
Target IDBE0004863
UniProt IDP25100
Regulation Typeantagonist
PubMed IDs26979079; 26655634; 21633249
CitationsRayner-Hartley E, Sedlak T: Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196. doi: 10.1161/JAHA.116.003196.@@Virsolvy A, Farah C, Pertuit N, Kong L, Lacampagne A, Reboul C, Aimond F, Richard S: Antagonism of Nav channels and alpha1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine. Sci Rep. 2015 Dec 10;5:17969. doi: 10.1038/srep17969.@@Zhao G, Walsh E, Shryock JC, Messina E, Wu Y, Zeng D, Xu X, Ochoa M, Baker SP, Hintze TH, Belardinelli L: Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol. 2011 Jun;57(6):639-47. doi: 10.1097/FJC.0b013e31821458e8.
GroupsApproved; Investigational
Direct ClassificationAnisoles
SMILESCOC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1
Pathways
PharmGKBPA164746007
ChEMBLCHEMBL1404